By Michele Maatouk
Date: Tuesday 07 Apr 2026
(Sharecast News) - California-based Gilead Sciences said on Tuesday that it has agreed to buy German clinical stage biotechnology group Tubulis for up to $5bn.
| Currency | US Dollars |
| Share Price | $ 150.93 |
| Change Today | $ 1.24 |
| % Change | 0.83 % |
| 52 Week High | $155.80 |
| 52 Week Low | $110.56 |
| Volume | 5,284,284 |
| Shares Issued | 1,241.00m |
| Market Cap | $187,304m |
| Beta | 0.01 |
| RiskGrade | 120 |
| Strong Buy | 8 |
| Buy | 15 |
| Neutral | 5 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 29 |

| Time | Volume / Share Price |
| 15:59 | 334 @ $150.91 |
| 15:59 | 100 @ $150.91 |
| 15:59 | 100 @ $150.91 |
| 15:59 | 100 @ $150.91 |
| 15:59 | 2,475 @ $150.90 |
You are here: research